BioTuesdays

Author - Melane Sampson

Scynexis Logo
Markets

Ladenburg cuts Scynexis PT to $6 from $10

Ladenburg Thalmann lowered its price target for Scynexis (NASDAQ:SCNX) to $6 from $10, citing another delay in development of an IV formulation of ibrexafungerp. The stock closed at $1.39 on August 10. “As successful as...

August 13, 2018
Corindus Logo
Markets

Stifel cuts Corindus Vascular Robotics to hold; PT $1

Stifel downgraded Corindus Vascular Robotics (NYSE AMER:CVRS) to “hold” from “buy” and slashed its price target to $1 from $3 after “disappointing” first half results and now-lower 2018-2020 sales projects. Shares of...

August 8, 2018
Mersana Therapeutics Logo
Markets

HCW cuts Mersana Therapeutics PT to $16 from $33

H.C. Wainwright slashed its price target for Mersana Therapeutics (NASDAQ:MRSN) to $16 from $33 after the company disclosed a partial clinical hold on its lead clinical program targeting HER2 expressing cancers. The...

July 20, 2018
Autolus Logo
Markets

WB starts Autolus Therapeutics at OP; valuation of $38

William Blair launched coverage of Autolus Therapeutics (NASDAQ:AUTL) with an “outperform” rating and risk-adjusted valuation of roughly $38. The stock closed at $20.86 on July 17. “Based on our view, the company’s next...

July 18, 2018
Adamas Pharmaceuticals Logo
Markets

HCW starts Adamas Pharma at buy; PT $45

H.C. Wainwright launched coverage of Adamas Pharmaceuticals (NASDAQ:ADMS) with a “buy” rating and $45 price target. The stock closed at $27.06 on July 13. Adamas’ lead product, GOCOVRI, was approved in August 2017 in...

July 16, 2018
Krystal Biotech Logo
Markets

Leerink starts Krystal Biotech at buy; FVE $29

Leerink launched coverage of Krystal Biotech (NASDAQ:KRYS) with a “buy” rating and $29 fair value estimate. The stock closed at $15.07 on July 9. Krystal is developing novel gene therapies for skin diseases, with lead...

July 10, 2018